NCT07154966Completed
Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy
Prospective Evaluation of Chemotherapy-Induced Taste Alterations, Sarcopenia, and Malnutrition in Patients With Gynecologic Malignancies Treated With Carboplatin and Paclitaxel
Source: ClinicalTrials.gov · Last updated 4 Sept 2025
Brief summary (registry, in English)
This observational study aims to evaluate chemotherapy-induced taste alterations, sarcopenia, and malnutrition in patients with gynecologic malignancies (ovarian, fallopian tube, and endometrial cancer) treated with standard carboplatin and paclitaxel. Eligible patients will receive six cycles of chemotherapy (carboplatin area under the curve \[AUC\] 5 + paclitaxel 175-200 mg/m², every 21 days), and assessments will be performed at baseline (before chemotherapy), after the 3rd cycle (\~9 weeks), and after the 6th cycle (\~18 weeks). Validated tools will be used, including the Chemotherapy-Induced Taste Alteration Scale (CITAS, Turkish validated, range 18-90; higher scores indicate greater severity of dysgeusia), the Patient-Generated Subjective Global Assessment (PG-SGA, Turkish validated, range 0-35; higher scores indicate worse nutritional status), and Computed Tomography (CT)-based Skeletal Muscle Index (SMI) at the L3 vertebra level.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 102 (actual)
- First submitted
- 24 Aug 2025
- Start date
- 15 Mar 2024
- Primary completion date
- 10 Jan 2025
- Lead sponsor
- Ankara Etlik City Hospital
- Diseases
- Endometrial cancer, Ovarian cancer
- NCT number
- NCT07154966
What you commit to
- Study type: Observational
- Participants enrolled: 102
- From 15 Mar 2024 to the primary completion date, 10 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with regimens other than carboplatin-paclitaxel or weekly protocols
- Prior systemic therapy (e.g., immunotherapy, targeted therapy) Initial treatment discontinuation due to progression, toxicity, or patient preference
Other illness
- Metastatic disease or palliative treatment setting
- Cognitive impairment or inability to provide informed consent
- Severe comorbid conditions (e.g., uncontrolled cardiac disease, end-stage renal failure, advanced liver failure)
Other
- Missing CT imaging at required timepoints
- Pregnancy or breastfeeding
- Inability to comply with study assessments or follow-up visits
Who the study is looking for
- Histologically confirmed diagnosis of non-metastatic ovarian, fallopian tube, or endometrial cancer
- Planned to receive adjuvant or neoadjuvant carboplatin-paclitaxel regimen (carboplatin AUC 5 + paclitaxel 175-200 mg/m² every 21 days)
- No prior chemotherapy
- Age ≥ 18 years, female
- Completion of 6 cycles of carboplatin-paclitaxel treatment
- Availability of CT imaging at baseline, after third cycle, and after sixth cycle
- Ability to provide written informed consent
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ankara Etlik City Hospital Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.